Cannabis Dosing Strategies in Family Medicine: Endocannabinoid System Research on Anxiety Relief
Clinical Takeaway
Cannabis flower products containing THC and CBD produced different day-to-day and longer-term effects on anxiety compared to edible products, highlighting that delivery method matters alongside cannabinoid content. Both CBD and combined THC plus CBD formulations showed more favorable anxiety outcomes than THC alone, consistent with CBD’s known anxiolytic properties. Patients using cannabis for anxiety should be counseled that product type and administration route meaningfully influence therapeutic outcomes.
#12 Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.
Citation: Rosa Luiza et al.. Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.. International journal of environmental research and public health. 2026. PMID: 41752306.
Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2
- Preclinical only
Abstract: Research shows that delta-9-tetrahydrocannabinol (THC) is linked to increased anxiety, while cannabidiol (CBD) may have anxiolytic effects. Cannabis use is often driven by coping with anxiety, though its daily impact on anxiety remains unclear. This study examined daily associations between cannabis use and anxiety across 30 days in adults who wanted to use cannabis for anxiety relief. Participants (N = 345) used flower or edible products ad libitum and were randomly assigned to groups by product type (CBD, THC, or THC + CBD). Each day, participants reported cannabis use in the past 24 h and rated their anxiety. Linear mixed-effects models tested whether anxiety changed over time, differed by cannabinoid group, and varied with use. Anxiety significantly decreased over the study period in both flower and edibles groups. In the flower group, THC + CBD and CBD products had greater decreases in anxiety (39.5% and 34.8%, respectively) compared to THC products (7.8%). In the edibles group, when participants used CBD products, this was associated with a 24.9% reduction in anxiety over the 30 days. Findings underscore the importance of distinguishing cannabis effects by product type and cannabinoid composition and suggest that CBD-dominant edibles were associated with less anxiety over time in this naturalistic study.
What This Study Teaches Us
In adults using cannabis for anxiety, CBD-dominant products (whether flower or edible) showed meaningful anxiety reductions over 30 days, while THC-only flower performed poorly. Edible CBD products appeared particularly effective, with a 24.9% reduction in anxiety over the study period.
Why This Matters Clinically
Many patients self-treat anxiety with cannabis without clear guidance on which product type actually works. This study suggests cannabinoid composition and delivery method matter as much as the decision to use cannabis at all, which could help clinicians counsel patients more specifically or help patients make more informed choices.
Study Snapshot
| Study Design | Randomized controlled trial with 30-day naturalistic observation period; participants assigned by product type (flower vs. edible) and cannabinoid group (CBD, THC, or THC+CBD) |
| Population | N = 345 adults motivated to use cannabis for anxiety relief. No demographic details provided in abstract. |
| Intervention | Ad libitum (self-directed) use of cannabis flower or edible products assigned by cannabinoid composition (CBD, THC, or THC+CBD) over 30 days |
| Primary Outcome | Daily anxiety ratings collected each day for 30 days; change in anxiety over time analyzed by product type and cannabinoid group |
| Key Result | Flower: CBD and THC+CBD groups showed 34.8% and 39.5% anxiety reduction respectively vs. 7.8% for THC-only. Edible: CBD products associated with 24.9% anxiety reduction over 30 days. |
Where This Paper Deserves Skepticism
The abstract provides minimal detail on baseline demographics, dropout rates, or whether anxiety was measured on a validated scale. The term ‘ad libitum’ use means dosing was uncontrolled and likely varied widely, making it impossible to know what dose of CBD actually drove the effect. No mention of funding source, blinding, or control for concurrent medications or psychotherapy. The 2026 publication date raises questions about peer review status. Most critically, a 30-day open-label observation cannot distinguish active cannabinoid effects from placebo, regression to the mean, or natural anxiety fluctuation in a self-selected sample seeking anxiety relief.
Dr. Caplan’s Take
I find the differential performance between THC-only and CBD-dominant products clinically interesting and consistent with what I hear in practice. That said, this is observational data in a self-selected population without rigorous anxiety measurement or dosing controls, so I’m not ready to make strong prescriptive claims. What I would tell a clinician is this: if a patient insists on cannabis for anxiety, the evidence here tentatively favors CBD or mixed CBD+THC products over THC-dominant ones, and edible CBD showed the steadiest response. But anxiety disorders remain best treated with first-line behavioral and pharmacologic evidence. Cannabis should be one conversation among many, not a default.
Clinical Bottom Line
Among motivated cannabis users, CBD-dominant and mixed CBD+THC products were associated with greater anxiety reductions than THC-only products over 30 days. This suggests product composition matters, but the open-label design and lack of dose control limit firm conclusions about clinical efficacy.
| |
Have thoughts on this? Share it:
